

Reimbursement Policy

Diagnosis of Idiopathic Environmental Intolerance

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [REIMBURSEMENT POLICY](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) |

I. Policy Description

Idiopathic environmental intolerance (IEI), formerly called multiple chemical sensitivity (MCS), is a subjective condition characterized by recurrent, nonspecific symptoms attributed to low levels of chemical, biologic, or physical agents in the absence of consistent objective diagnostic physical findings or laboratory tests that define an illness (AAAAI, 1999; ACOEM, 1999; Black & Temple, 2021).

II. Indications and/or Limitations of Coverage

NOTE: This topic was previously addressed within BCBST's Complementary & Alternative Medicine policy as investigational. As part of the process of adopting Avalon's policy position, BCBST will now address this topic within this separate reimbursement policy document.

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in Section VIII of this policy document.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient's illness.

- 1) Laboratory tests designed to affirm the diagnosis of idiopathic environmental illness **DO NOT MEET COVERAGE CRITERIA.**
- 2) Screening blood, saliva, serum, plasma, urine, and/or stool samples for volatile solvents, organic acids, and organophosphates **DO NOT MEET COVERAGE CRITERIA** in all circumstances including but not limited to the following compounds:
 - a) 2-methylhippurate
 - b) 2-methylpentane
 - c) 3-methylpentane
 - d) 3,4-dihydroxyphenylpropionate
 - e) 4-nonylphenol

Reimbursement Policy

- f) alpha-keto-beta-methylvalerate
 - g) alpha-ketoisovalerate
 - h) arabinitol
 - i) atrazine or atrazine mercapturate
 - j) benzene
 - k) benzoate
 - l) bisphenol A (BPA)
 - m) diethyldithiophosphate (DEDTP), diethylthiophosphate (DETP), dimethyldithiophosphate (DMDTP), dimethylthiophosphate (DMTP)
 - n) ethylbenzene
 - o) hexane
 - p) Hippurate
 - q) Indican
 - r) Picolinate
 - s) Polychlorinated biphenyls (PCBs)
 - t) Quinolate
 - u) Styrene
 - v) Taurine
 - w) Toluene
 - x) Triclosan
 - y) Xylene
- 3) Phthalates and parabens profiling using a blood, serum, plasma, saliva, urine, and/or stool sample **DOES NOT MEET COVERAGE CRITERIA.**
- 4) Chlorinated pesticides, including DDE and DDT, profiling in asymptomatic patients using a blood, serum, plasma, saliva, urine, and/or stool sample **DOES NOT MEET COVERAGE CRITERIA.**
- 5) Testing blood, serum, plasma, saliva, urine, and/or stool samples for carnitine sufficiency, oxidative stress and antioxidant sufficiency, detoxification adequacy, methylation sufficiency status, lipoic acid and CoQ10 sufficiency, and/or intestinal hyperpermeability **DO NOT MEET COVERAGE CRITERIA** in asymptomatic individuals and/or during general encounters. These tests include, but are not limited to, the following:
- a) Amino acid testing except for newborn screening and for documented metabolic disorders
 - b) Carotene/beta-carotene

Reimbursement Policy

- c) Citrate
 - d) Vanillylmandelic acid (VMA) testing except for use in diagnosis of neuroblastoma or neuroendocrine tumors or for monitoring effectiveness of treatment of cancer
 - e) Homovanillic acid (HVA) testing except for use in diagnosis and evaluating neuroblastomas
 - f) 5-hydroxyindolacetic acid (5-HIAA) testing except for use in diagnosis and evaluating carcinoid syndrome or for staging, treatment, and surveillance of suspected neuroendocrine tumors
 - g) Elastase except for pancreatic insufficiency
 - h) Fat differentiation testing, qualitative and quantitative
 - i) CoQ10
- 6) Testing blood, serum, plasma, saliva, urine, and/or stool samples for vitamin sufficiency, mineral sufficiency, and/or nutritional analysis **DO NOT MEET COVERAGE CRITERIA** in asymptomatic individuals and/or during general encounters without abnormal findings. These tests include, but are not limited to, the following:
- a) Amino acid testing except for newborn screenings or for documented metabolic disorders
 - b) Allergen-specific IgG testing for screening food sensitivities, vitamin sufficiency, or mineral sufficiency
 - c) Carotene/beta-carotene
 - d) Citrate
 - e) Vanillylmandelic acid (VMA) testing except for use in diagnosis of neuroblastoma or neuroendocrine tumors or for monitoring effectiveness of treatment of cancer
 - f) Homovanillic acid (HVA) testing except for use in diagnosis and evaluating neuroblastomas
 - g) 5-hydroxyindolacetic acid (5-HIAA) testing except for use in diagnosis and evaluating carcinoid syndrome or for staging, treatment, and surveillance of suspected neuroendocrine tumors
 - h) Lipid peroxides
 - i) Behenic acid
 - j) Lignoceric acid
 - k) Fat differentiation testing, qualitative and quantitative
 - l) Prealbumin
- 7) The use of a breath hydrogen and/or breath methane test to assess or diagnose the following conditions **DOES NOT MEET COVERAGE CRITERIA**:
- a) Idiopathic environmental intolerance
 - b) Food allergies and sensitivities

Reimbursement Policy

- c) Carbohydrate sensitivity or intolerance, including but not limited to, lactose sensitivity, lactose intolerance, and/or lactase deficiency
 - d) Bacterial overgrowth, including but not limited to, small intestinal bacterial overgrowth [SIBO]
 - e) Digestive disorders
 - f) Constipation, diarrhea, or flatulence
 - g) Neurological/neuromuscular disorders, including but not limited to, Parkinson disease and fibromyalgia
 - h) Rosacea
 - i) Obesity
 - j) As part of a wellness visit and/or general encounter without abnormal findings
- 8) Testing blood, serum, urine, cerebrospinal fluid, fingernails, hair, and/or stool sample for metals, including but not limited to, aluminum, arsenic, cadmium, chromium, copper, lead, magnesium, manganese, mercury, molybdenum, nickel, zinc, and heavy metals not otherwise specified **DO NOT MEET COVERAGE CRITERIA** in asymptomatic individuals and/or general encounters without abnormal findings.

III. Reimbursement Policy

- 1) For 83918 (Organic acids; total, quantitative, each specimen), a maximum of 2 units per date of service is **ALLOWED**.
- 2) For 83919 (Organic acids; qualitative, each specimen), a maximum of 1 unit per date of service is **ALLOWED**.
- 3) For 83921 (Organic acid, single, quantitative), a maximum of 2 units per date of service is **ALLOWED**.
- 4) For 82127 (Amino acids; single, qualitative, each specimen), a maximum of 1 unit per date of service is **ALLOWED**.
- 5) For 82136 (Amino acids, 2 to 5 amino acids, quantitative, each specimen), a maximum of 2 units per date of service is **ALLOWED**.
- 6) For 82139 (Amino acids, 6 or more amino acids, quantitative, each specimen), a maximum of 2 units per date of service is **ALLOWED**.
- 7) For 84585 (Vanillylmandelic acid (VMA), urine), a maximum of 1 unit per date of service is **ALLOWED**.
- 8) For 83150 (Homovanillic acid (HVA)), a maximum of 1 unit per date of service is **ALLOWED**.
- 9) For 83497 (Hydroxyindolacetic acid, 5-(HIAA)), a maximum of 1 unit per date of service is **ALLOWED**.

Reimbursement Policy

10) For 82656 (Elastase, pancreatic (EL-1), fecal, qualitative, or semi-quantitative), a maximum of 1 unit per date of service is **ALLOWED**.

IV. Table of Terminology

Term	Definition
5-HIAA	5-hydroxyindolacetic acid
AAAAI	American College of Physicians and the American Academy of Allergy and
ACOEM	American College of Occupational and Environmental Medicine
ACP	American College of Physicians
AMA	American Medical Association
ANA	Antinuclear antibodies
AND	The Academy of Nutrition and Dietetics
ANSES	French Agency for Food, Environmental and Occupational Health & Safety
BPA	Bisphenol A
BT	Breath test
CDSA	Comprehensive digestive stool analysis
CLIA '88	Clinical Laboratory Improvement Amendments of 1988
CMS	Centers for Medicare and Medicaid Services
CoQ10	Coenzyme Q10/ubiquinone-10
DDE	Dichlorodiphenyldichloroethylene
DDT	Dichlorodiphenyltrichloroethane
DEDTP	Diethyldithiophosphate
DETP	Diethylthiophosphate
DMDTP	Dimethyldithiophosphate
DMTP	Dimethylthiophosphate
DNMCC	Does not meet coverage criteria
EESI	Environmental exposure and sensitivity intolerance
EHS	Electromagnetic hypersensitivity
EL-1	Elastase (pancreatic)
ESPGHAN	European Society for Pediatric Gastroenterology, Hepatology, and Nutrition
FDA	Food and Drug Administration
FMV®	First morning void
GC	Gas chromatography
GHBT	Glucose hydrogen breath tests
GI	Gastrointestinal
HPLC	High performance liquid chromatography

Reimbursement Policy

HVA	Homovanillic acid
IBS	Irritable bowel syndrome
IEI	Idiopathic environmental intolerance
IEI-EMF	Idiopathic environmental intolerance attributed to electromagnetic fields
IgE	Immunoglobulin E
IgG	Immunoglobulin G
LBT	Lactulose breath test
LC	Liquid chromatography
LDTs	Laboratory-developed tests
LHBT	Lactulose hydrogen breath test
MCS	Multiple chemical sensitivity
MS	Mass spectrometry
NASPGHAN	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition
ONE	Optimal nutritional evaluation
PCBs	Polychlorinated biphenyls
PHQ-9	Patient Health Questionnaire-9
SIBO	Small intestinal bacterial overgrowth
VMA	Vanillylmandelic acid
WHO	World Health Organization

V. Scientific Background

Patients with idiopathic environmental intolerance (IEI) typically report sensitivity to multiple, chemically unrelated substances and become ill due to a wide range of nonspecific symptoms when exposed. Symptoms may include anxiety, shortness of breath, chest pain, and more. Psychiatric disorders may also be at the core of the IEI patient (Black & Temple, 2021). The mean age of patients reporting IEI is between 30 and 40 years, women are diagnosed more than men, and individuals who are married are significantly more likely to be diagnosed with IEI than those who are not (Black & Temple, 2021). IEI also occurs in 40% of people with chronic fatigue syndrome and in 16% of people with fibromyalgia (Black et al., 2020).

The symptoms of IEI are nonspecific, ambiguous and common in the general population. There is no characteristic set of symptoms and ultimately no major differences between patients self-reporting IEI and those that do not. Virtually any symptom can be considered a symptom of IEI (Black & Temple, 2021). Within the definition of multiple chemical sensitivity (MCS), identified symptoms included “asthmatic-like, skin irritation, dermatitis, migraine, dysuria, dyspepsia, symptoms of supposed sensitization to food, persistent arthromial pain, vertigo, vestibular impairment,” with 80% of patients experiencing “asthenia, arthromial pain, dyspepsia, coriza, eructation, chest pain, insomnia” (Quarato et al., 2020). The classification of IEI as a distinct medical disorder is also in question, as a lack of reliable case reports, lack of consistent findings or laboratory results, and reliance on surveys or self-reporting all cloud the condition and understanding of this disorder (Black & Temple, 2021).

Reimbursement Policy

Recently, many articles have been published suggesting a relationship between electromagnetic fields and IEI. Electromagnetic fields may include radiofrequencies from telecommunication devices (Eltiti et al., 2018; Huang et al., 2018), Wi-Fi and base stations (ANSES, 2018). For an unknown reason, these individuals claim to react to the exposure of certain electromagnetic triggers that most people can tolerate without issues; these triggers are below established toxicological and hazardous thresholds. ANSES (2018) researched the relationship between electric field exposure and IEI symptoms and stated that “either the symptoms experienced by EHS [electromagnetic hypersensitivity] individuals are not caused by exposure to electromagnetic fields and there are no quantifiable biological and/or physiological abnormalities when they are exposed to electromagnetic fields (assumption 1) or the absence of results is due to the methodological limitations of the provocation studies (subject selection, sample size, exposure type, etc.) (assumption 2).” These findings were corroborated by Schmiedchen et al. (2019), who, in their systematic review of articles pertaining to EHS, stated, “limitations in design, conduct and analysis could therefore have given rise to either false positive for false negative results,” and that the “nocebo effect or medical/mental disorders may explain the complaints in many individuals.” Characteristic symptoms of EHS include sleep and circadian rhythm disorders, migraines and headaches, hypersensitivity, and other related syndromes and disorders such as fibromyalgia, tinnitus and MCS (ANSES, 2018).

Tests such as elimination diets, food challenges, and provocation-neutralization tests have been used to test for food or chemical sensitivities. Immunological tests or tests measuring the amount of various chemicals in body tissues have also been performed (Black & Temple, 2021). In fact, testing for a wide range of autoantibodies is generally discouraged, as “pretest probability is low, and false-positive results are far more likely than true-positive results; a weakly positive ANA [antinuclear antibodies] is present in about 20% of the population” (Black et al., 2020). However, these assessments are typically not rigorous enough to provide strong evidence; for example, these tests are often not performed blinded or with placebo controls. No unusual laboratory findings have been reliably linked to IEI (Black & Temple, 2021). Due to the vast number of causes, symptoms, responses, and general heterogeneity of this condition, it may be very difficult to provide a scientifically valid or useful test. Worse, testing may even exacerbate or increase the number of symptoms of a patient. Physicians should use caution in testing for reassurance of patients as negative findings may increase anxiety instead (Barsky & Borus, 1999; Black & Temple, 2021).

Proprietary Testing

Due to the number of symptoms that may be considered part of IEI, there are a corresponding amount of tests performed. These tests are generally unnecessary as the condition itself is far too ambiguous to reliably test for and any test can be ordered under the guise of IEI. For example, assessment of factors such as elastase, stool culturing, or fat differentiation may all be done for the sake of IEI treatment. These tests may have legitimate medical purposes (for instance a stool culture may be useful for numerous conditions) but their use for IEI is essentially none, as IEI itself carries no reliable characteristics to test for. Other tests that evaluate a tangentially relevant analyte, such as micronutrient panels or a lactose intolerance breath test (BT), may be done for IEI’s sake as well. Since virtually any symptom or sign can be called IEI, these tests are sometimes ordered for nonspecific or subjective symptoms such as fatigue or pain. However, these tests cannot provide any useful results because of the dubious nature of IEI itself.

Reimbursement Policy

Another commonly used test for IEI are panels that test multiple factors in one. For example, the Triad Bloodspot Profile offered by Genova Diagnostics measures organic acid levels, “the level of IgG4 reactions for 30 common foods,” and “essential amino acid imbalances” (Genova, 2021d). Genova offers several similar panels, such as the Organix Comprehensive Profile (which tests 46 analytes for subjective symptoms such as depression, weight issues and chemical sensitivities) (Genova, 2021c), the NutrEval FMV [first morning void] (which tests 118 analytes for symptoms such as fatigue, weight issues, and sports fitness optimization) (Genova, 2021a) and the Allergix IgG4 Food Antibodies (which tests 90 foods for sensitivity). Genova Diagnostics also offers the GI Effects Profile (advanced stool tests for the management of gastrointestinal [GI] health), a full line of allergy testing and assessment tests (measuring IgG and IgE food antibodies, inhalants, molds and spices), the Ion Profile (which evaluates various types of organic, amino and fatty acids as well as nutrient and toxic elements), the Comprehensive Digestive Stool Analysis (CDSA) 2.0 Profile with Parasitology (evaluates the microbiome, digestion and absorption), and SIBO Profile tests (breath tests which measure methane gases and exhaled hydrogen) (Genova, 2020).

An evaluation of symptoms of IEI patients includes a history, physical examination, and laboratory tests (complete blood count, serum electrolytes and glucose, urine analysis) with further testing guided by reported symptoms. An occupational or environmental history is also useful as patients typically report problems from chemical exposure (Black & Temple, 2021). A questionnaire such as the “Environmental Exposure and Sensitivity Intolerance” (EESI) may be used for an initial screening (Rossi & Pitidis, 2018). A psychiatric history is also recommended as psychiatric disorders are often co-morbid with IEI. A screening questionnaire such as the Patient Health Questionnaire (PHQ-9) can be used to identify psychiatric conditions in an IEI patient (Black & Temple, 2021; Gilbody et al., 2007).

Micronutrients are the essential vitamins and minerals required by the body for proper functioning. Panels have been developed which evaluate intracellular levels of essential vitamins and minerals. These panels may also be used on IEI patients. This may help to identify nutritional deficiencies in otherwise healthy patients or in patients suffering from some type of disease. SpectraCell Laboratories have developed the Micronutrient Test Panel, which is able to measure 31 vitamins, minerals, metabolites, amino acids, fatty acids and antioxidants; this test also measures how these micronutrients affect cellular functioning in an individual (SpectraCell, 2021). SpectraCell Laboratories have also developed the SPECTROX™, claiming it measures total antioxidant function in an individual, reporting on the repair mechanisms and net ability of each individual’s cells (SpectraCell, 2008). As noted above, Genova Diagnostics has developed the NutrEval FMV that measures 118 markers, including amino acids, fatty acids and organic acids (Genova, 2021a). ONE (Optimal Nutritional Evaluation) FMV, also by Genova Diagnostics, is a urine-based nutritional test which assesses “the functional need for antioxidants, B-vitamins, minerals, digestive support and amino acids” (Genova, 2021b). The company notes that the ONE FMV test may be used for patients with mood disorders, fatigue, digestive issues, weight problems, general health, dietary guidance and fitness. Another nutrient panel blood test, developed by Life Extension, measures vitamin B12, folate, vitamin D 25-hydroxy, vitamin A, vitamin C, selenium, zinc, CoQ10 (coenzyme Q10) and magnesium (LifeExtension, 2020). Finally, Vibrant America provides a test which measures approximately 40 intracellular and extracellular vitamins, minerals, fatty acids, amino acids and antioxidants (Vibrant, 2017).

Clinical Utility and Validity

Reimbursement Policy

Very little information suggests that the intracellular micronutrient analysis assists with positive health outcomes. Houston (2013) published an article on the role of vitamins, minerals and overall nutrition in the prevention and treatment of hypertension. This article reviewed hypertension-related clinical trials that include information on the “efficacy of nutrition, weight loss, exercise, and nutritional supplements, vitamins, minerals, and antioxidants” (Houston, 2013). Approximately 3338 patients were treated with micronutrient testing over a five-year period, with 20% of these patients exhibiting abnormally high blood pressure. After six months, 62% of the hypertensive patients reached lower blood pressure goals. Hence, the author states that the diagnosis and treatment of various nutritional deficiencies can decrease the number of cardiac events as well as reduce blood pressure and improve vascular biology. However, data for the control group not treated with micronutrients was not provided for comparison.

Another technique that has been used to assess nutritional status is the measurement of the hepatic proteins prealbumin and albumin. However, it seems that a physical examination has evolved as the main technique to diagnose malnutrition in a clinical setting. “The current consensus is that laboratory markers are not reliable by themselves but could be used as a complement to a thorough physical examination” in a malnutrition diagnosis (Bharadwaj et al., 2016). The Academy of Nutrition and Dietetics (AND) also do not accept albumin and prealbumin as a diagnostic tool for malnutrition and state that “There is no laboratory test that is both sensitive to and specific for protein-calorie malnutrition” (AND, 2017).

IEI patients may also report bowel irritability. Small intestinal bacterial overgrowth (SIBO) occurs when excessive aerobic and anaerobic bacteria colonize the small intestine; these bacteria are not typically found in the colon and can cause chronic diarrhea and malabsorption (Pimentel, 2020). SIBO may be diagnosed by a breath test. However, a validated gold standard method for diagnosing SIBO has not been indicated (Rezaie et al., 2017). The SIBO breath test uses carbohydrates in a simple, non-invasive and widely available testing method. A carbohydrate substrate (such as lactulose or glucose) is administered to the patient, which leads to the production of an analyte such as hydrogen or methane. “In individuals without SIBO, the administration of lactulose results in a single peak in breath hydrogen/methane within two to three hours due to the metabolism of lactulose by colonic flora. In patients with SIBO, administration of lactulose results in an early peak in breath hydrogen/methane levels due to metabolism by small bowel bacteria” (Pimentel, 2020). As noted above, Genova Diagnostics has developed the SIBO Profile test which is a two or three hour breath test that measures methane gases and exhaled hydrogen (Genova, 2020). This test requires the patient to ingest a lactulose solution.

Bratten et al. (2008) completed a study with 224 patients with irritable bowel syndrome (IBS) and 40 controls. A lactulose breath test (LBT) was used to measure methane and hydrogen production to identify patients with IBS. Results showed that “The majority of patients with IBS and healthy subjects meet criteria for an “abnormal” LBT using previously published test criteria, and groups are not discriminated using this diagnostic method” (Bratten et al., 2008). The authors then questioned the utility of an LBT to diagnose IBS as the testing did not discriminate between IBS patients and healthy controls. A more recent study by Ghoshal et al. (2014) evaluated 80 patients with IBS for SIBO. Culture had previously diagnosed 15/80 patients with SIBO. Both lactulose and glucose hydrogen breath tests (LHBT and GHBT, respectively) were used to measure SIBO. The authors conclude that “The specificity of GHBT was 100%, but the sensitivity of this test and the diagnostic performances of LHBT and breath methane were all very poor” (Ghoshal et al., 2014).

Reimbursement Policy

VI. Guidelines and Recommendations

Due to the dubious nature of this condition, several prominent medical studies have regarded this condition with suspicion. In 1992, the American Medical Association (AMA) stated that multiple chemical sensitivity (now IEI) should not be recognized as a syndrome until accurate, reproducible, and well-controlled studies can be done (AMA, 1992). Other societies such as the American College of Physicians and the American Academy of Allergy and Immunology hold similar views (AAAAI, 1986; ACP, 1989).

American Academy of Allergy, Asthma and Immunology (AAAAI)

In 2006, AAAAI referenced IEI in their position statement on the medical effects of mold stating that testing many nonvalidated immune based tests, as had been done to suggest an immunologic basis for IEI (MCS), is expensive, not useful or valid, and should be discouraged (Bush et al., 2006).

American College of Occupational and Environmental Medicine (ACOEM)

In 1999, the ACOEM published a position statement that stated there have been no consistent physical findings or laboratory abnormalities in IEI (then called MCS) patients and recommended that a generalized clinical approach, such as establishing a therapeutic alliance and avoiding unnecessary tests, would be useful in the management of other nonspecific medical syndromes (ACOEM, 1999).

French Agency for Food, Environmental and Occupational Health & Safety (ANSES) Appraisal-Collective Expertise Report

An ANSES expert committee published an opinion piece regarding the expert appraisal on EHS or IEI due to electromagnetic fields. This committee did not find any conclusive results regarding IEI and therefore does not recommend any specific testing methods for this ailment, other than the psychological testing of patients.

Consensus Document (1999)

An international document, created by 89 clinicians and researchers with broad experience in the field, aimed to establish consensus criteria for MCS. The recognition criteria of MCS set forth by this expert panel are as follows:

- Chronic condition
- Reproducible symptoms with repeated chemical exposure
- Low exposure levels cause syndrome to occur
- Removal of offending agents cause symptoms to subside
- There are responses to chemically unrelated substances ("Multiple chemical sensitivity: a 1999 consensus," 1999)

Reimbursement Policy

The 1999 Consensus Document is the most widely used criteria for recognition of MCS (Martini et al., 2013).

North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)

The NASPGHAN and ESPGHAN have stated that “Clinicians should familiarize themselves with the limitations of nutritional biomarkers in the context of chronic liver disease” but do not give specific recommendations regarding nutritional laboratory testing (Mouzaki et al., 2019).

World Health Organization

The WHO published guidelines on the micronutrient intake in children with severe acute malnutrition. The guidelines recommend that the weight-for-height/weight-for-length status should be measured by clinicians to determine malnutrition. Micronutrient laboratory testing is not mentioned by the WHO.

The North American Expert Consensus Guidelines

A team of experts have published guidelines on breath tests including their use for a SIBO diagnosis. The authors have provided the following recommendations:

- “Current small bowel culture techniques are not satisfactory for the assessment of SIBO.
- If culture is considered for diagnosis of SIBO, based on the current evidence, we suggest the threshold of $>10^3$ c.f.u./ml for the definition of SIBO.
- We suggest breath testing in the diagnosis of small intestinal bacterial overgrowth.
- Until a true gold standard is established, we suggest breath testing in assessing the presence of antibiotic responsive microbial colonization of the gastrointestinal tract.
- We suggest to evaluate for excessive methane excretion on breath test in association with clinical constipation and slowing of gastrointestinal transit.
- We suggest that breath testing should not be used for assessment of orocecal transit time.
- We suggest breath testing for the diagnosis of carbohydrate maldigestion syndromes.
- We suggest breath testing in the assessment of conditions with bloating
- We suggest that fructose and lactose breath test should be performed for at least 3 hours.
- We suggest that the presence of bacterial overgrowth should be ruled out before performing lactose or fructose breath testing (Rezaie et al., 2017).”

It may be worth noting that the above recommendation of LHBT testing for SIBO was publicly criticized by Usai-Satta et al. (2018) due to high false positive rates and a low sensitivity. The authors state that “in our opinion, LHBT should be neither recommended nor suggested to detect SIBO in the clinical practice. Despite a low sensitivity, Glucose BT [breath test] remains the most accurate BT for non-invasive diagnosis of SIBO (Usai-Satta et al., 2018).”

The Academy of Nutrition and Dietetics

Reimbursement Policy

The AND note that “serum proteins such as albumin and prealbumin are not included as defining characteristics of malnutrition because evidence analysis shows that serum levels of these proteins do not change in response to changes in nutrient intake. Hepatic proteins are not indicators of nutritional status, but are rather indicators of morbidity and mortality, and recovery from acute and chronic disease (AND, 2017).”

VII. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

No specific U.S. Food and Drug Administration (FDA) approval or clearance of a test for idiopathic environmental intolerance was found. Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

VIII. Evidence-based Scientific References

- AAAAI. (1986). Clinical ecology. Executive Committee of the American Academy of Allergy and Immunology. *J Allergy Clin Immunol*, 78(2), 269-271.
- AAAAI. (1999). Idiopathic environmental intolerances. American Academy of Allergy, Asthma and Immunology (AAAAI) Board of Directors. *J Allergy Clin Immunol*, 103(1 Pt 1), 36-40.
- ACOEM. (1999). ACOEM position statement. Multiple chemical sensitivities: idiopathic environmental intolerance. College of Occupational and Environmental Medicine. *J Occup Environ Med*, 41(11), 940-942.
- ACP. (1989). Clinical ecology. American College of Physicians. *Ann Intern Med*, 111(2), 168-178.
- AMA. (1992). Clinical ecology. Council on Scientific Affairs, American Medical Association. *Jama*, 268(24), 3465-3467.
- AND. (2017). *Should Albumin and Prealbumin Be Used as Indicators for Malnutrition?* [https://jandonline.org/article/S2212-2672\(17\)30444-6/pdf](https://jandonline.org/article/S2212-2672(17)30444-6/pdf)
- ANSES. (2018). *OPINION of the French Agency for Food, Environmental and Occupational Health & Safety regarding the expert appraisal on “electromagnetic hypersensitivity (EHS) or idiopathic environmental intolerance attributed to electromagnetic fields (IEI-EMF)”*. <https://www.anses.fr/en/system/files/AP2011SA0150EN.pdf>
- Barsky, A. J., & Borus, J. F. (1999). Functional somatic syndromes. *Ann Intern Med*, 130(11), 910-921.

Reimbursement Policy

- Bharadwaj, S., Ginoya, S., Tandon, P., Gohel, T. D., Guirguis, J., Vallabh, H., Jevenn, A., & Hanouneh, I. (2016). Malnutrition: laboratory markers vs nutritional assessment. *Gastroenterol Rep (Oxf)*, 4(4), 272-280. <https://doi.org/10.1093/gastro/gow013>
- Black, D., & Temple, S. (2021, May 29). *Idiopathic environmental intolerance (multiple chemical sensitivity)*. UptoDate. <https://www.uptodate.com/contents/idiopathic-environmental-intolerance-multiple-chemical-sensitivity>
- Black, D. W., Carver, R. J., & Carver, L. A. (2020, July). *Idiopathic Environmental Intolerance (Multiple Chemical Sensitivity; Environmental Illness)*. Merck Sharp & Dohme Corp. <https://www.merckmanuals.com/professional/special-subjects/idiopathic-environmental-intolerance/idiopathic-environmental-intolerance>
- Bratten, J. R., Spanier, J., & Jones, M. P. (2008). Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. *Am J Gastroenterol*, 103(4), 958-963. <https://doi.org/10.1111/j.1572-0241.2008.01785.x>
- Bush, R. K., Portnoy, J. M., Saxon, A., Terr, A. I., & Wood, R. A. (2006). The medical effects of mold exposure. *J Allergy Clin Immunol*, 117(2), 326-333. <https://doi.org/10.1016/j.jaci.2005.12.001>
- Eltiti, S., Wallace, D., Russo, R., & Fox, E. (2018). Symptom Presentation in Idiopathic Environmental Intolerance With Attribution to Electromagnetic Fields: Evidence for a Nocebo Effect Based on Data Re-Analyzed From Two Previous Provocation Studies. *Front Psychol*, 9, 1563. <https://doi.org/10.3389/fpsyg.2018.01563>
- Genova. (2020). *Testing Services Overview*. <https://www.gdx.net/files/clinicians/how-to-order/Genova-Diagnostics-Testing-Services-Overview.pdf>
- Genova. (2021a). *NutrEval® FMV*. Retrieved 1/5/21 from <https://www.gdx.net/product/nutreval-fmv-nutritional-test-blood-urine>
- Genova. (2021b). *ONE (Optimal Nutritional Evaluation) FMV™*. Retrieved 1/5/21 from <https://www.gdx.net/product/one-fmv-nutritional-test-urine>
- Genova. (2021c). *Organix® Comprehensive Profile - Urine*. Retrieved 1/5/21 from <https://www.gdx.net/product/organix-comprehensive-profile-metabolic-function-test-urine>
- Genova. (2021d). *TRIAD® Bloodspot Profile*. Retrieved 1/5/21 from <https://www.gdx.net/product/triad-bloodspot-profile-metabolic-nutritional-test-blood-spot>
- Ghoshal, U. C., Srivastava, D., Ghoshal, U., & Misra, A. (2014). Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. *Eur J Gastroenterol Hepatol*, 26(7), 753-760. <https://doi.org/10.1097/meg.0000000000000122>
- Gilbody, S., Richards, D., Brealey, S., & Hewitt, C. (2007). Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med*, 22(11), 1596-1602. <https://doi.org/10.1007/s11606-007-0333-y>
- Houston, M. C. (2013). The role of nutrition, nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. *Altern Ther Health Med*, 19 Suppl 1, 32-49. <https://www.ncbi.nlm.nih.gov/pubmed/23981465>
- Huang, P. C., Cheng, M. T., & Guo, H. R. (2018). Representative survey on idiopathic environmental intolerance attributed to electromagnetic fields in Taiwan and comparison with the international literature. *Environ Health*, 17(1), 5. <https://doi.org/10.1186/s12940-018-0351-8>
- LifeExtension. (2020). *Nutrient Panel Blood Test*. <https://www.lifeextension.com/lab-testing/itemlc100024/nutrient-panel-blood-test>

Reimbursement Policy

- Martini, A., Iavicoli, S., & Corso, L. (2013). Multiple chemical sensitivity and the workplace: current position and need for an occupational health surveillance protocol. *Oxid Med Cell Longev*, 2013, 351457. <https://doi.org/10.1155/2013/351457>
- Mouzaki, M., Bronsky, J., Gupte, G., Hojsak, I., Jahnel, J., Pai, N., Quiros-Tejeira, R. E., Wieman, R., & Sundaram, S. (2019). Nutrition Support of Children With Chronic Liver Diseases: A Joint Position Paper of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr*, 69(4), 498-511. <https://doi.org/10.1097/mpg.0000000000002443>
- Multiple chemical sensitivity: a 1999 consensus. (1999). *Arch Environ Health*, 54(3), 147-149. <https://doi.org/10.1080/00039899909602251>
- Pimentel, M. (2020, February 27). *Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis*. <https://www.uptodate.com/contents/small-intestinal-bacterial-overgrowth-clinical-manifestations-and-diagnosis>
- Quarato, M., De Maria, L., Caputi, A., Cavone, D., Cannone, E. S. S., Mansi, F., Gatti, M. F., & Vimercati, L. (2020). A case report of idiopathic environmental intolerance: A controversial and current issue. *Clin Case Rep*, 8(1), 79-85. <https://doi.org/10.1002/ccr3.2535>
- Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. *Am J Gastroenterol*, 112(5), 775-784. <https://doi.org/10.1038/ajg.2017.46>
- Rossi, S., & Pitidis, A. (2018). Multiple Chemical Sensitivity: Review of the State of the Art in Epidemiology, Diagnosis, and Future Perspectives. *J Occup Environ Med*, 60(2), 138-146. <https://doi.org/10.1097/jom.0000000000001215>
- Schmiedchen, K., Driessen, S., & Oftedal, G. (2019). Methodological limitations in experimental studies on symptom development in individuals with idiopathic environmental intolerance attributed to electromagnetic fields (IEI-EMF) - a systematic review. *Environ Health*, 18(1), 88. <https://doi.org/10.1186/s12940-019-0519-x>
- SpectraCell. (2021). *Micronutrient Test Panel*. Retrieved 1/5/21 from <https://www.spectracell.com/micronutrient-test-panel>
- SpectraCell. (2008). *SPECTROX™ (Total Antioxidant Function)*. https://assets.speakcdn.com/Assets/2606/0e2022931_supplement-spectrox.pdf
- Usai-Satta, P., Giannetti, C., Oppia, F., & Cabras, F. (2018). The North American Consensus on Breath Testing: The Controversial Diagnostic Role of Lactulose in SIBO. *Am J Gastroenterol*, 113(3), 440. <https://doi.org/10.1038/ajg.2017.392>
- Vibrant. (2017). *MICRONUTRIENTS*. <https://www.vibrant-america.com/micronutrient/>